Axsome Therapeutics financials
$186.14−4.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218.4M | $191.2M | $196.0M | $171.0M | $150.0M | $121.5M | $118.8M | $104.8M | $87.2M | $75.0M | $71.5M | $57.8M |
| Gross profit | $204.8M | $176.5M | $183.7M | $159.1M | $136.6M | $111.7M | $108.3M | $96.3M | $79.1M | $68.7M | $64.2M | $51.3M |
| Gross margin | 93.8% | 92.3% | 93.7% | 93.0% | 91.0% | 91.9% | 91.1% | 91.9% | 90.8% | 91.6% | 89.7% | 88.7% |
| Operating income | -$49.6M | -$63.4M | -$27.0M | -$46.1M | -$36.7M | -$57.0M | -$72.6M | -$62.6M | -$78.0M | -$67.3M | -$98.3M | -$62.1M |
| Net income | -$51.3M | -$64.5M | -$28.6M | -$47.2M | -$48.0M | -$59.4M | -$74.9M | -$64.6M | -$79.3M | -$68.4M | -$98.7M | -$62.2M |
| Net margin | −23.5% | −33.8% | −14.6% | −27.6% | −32.0% | −48.9% | −63.1% | −61.7% | −91.0% | −91.1% | −137.9% | −107.6% |
| Diluted EPS | $-0.99 | $-1.26 | $-0.56 | $-0.94 | $-0.97 | $-1.22 | $-1.54 | $-1.34 | $-1.67 | $-1.44 | $-2.08 | $-1.32 |
| EBITDA | -$47.9M | -$61.7M | -$25.2M | -$44.4M | -$35.0M | -$55.3M | -$70.9M | -$60.9M | -$76.4M | -$65.4M | -$98.3M | -$60.4M |
| Operating cash flow | -$33.0M | -$20.7M | -$18.7M | $1.0M | -$32.4M | -$43.4M | -$26.2M | -$18.6M | -$30.1M | -$53.5M | -$30.4M | -$53.5M |
| Free cash flow | -$33.4M | -$20.8M | -$18.7M | $988.0K | -$32.4M | -$43.7M | -$26.2M | -$18.7M | -$30.2M | -$53.6M | -$30.4M | -$53.9M |
| Diluted shares | 51.8M | 51.2M | 50.7M | 50.0M | 49.4M | 48.9M | 48.5M | 48.1M | 47.6M | 47.4M | 47.4M | 47.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $319.9M | $305.1M | $322.9M | $325.3M | $303.0M | $300.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $197.0M | $193.7M | $192.0M | $192.3M | $191.3M | $185.1M |
| Total assets | $761.4M | $713.6M | $689.8M | $669.3M | $639.8M | $596.7M |
| Total liabilities | $678.1M | $659.0M | $601.5M | $595.5M | $566.7M | $543.5M |
| Shareholders' equity | $83.3M | $54.6M | $88.3M | $73.7M | $73.1M | $53.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology